Issue Simulation cannot count as regulatory evidence because shared validation standards do not exist

Summary

The Dubai Future Foundation outlook argues that quantum simulation cannot yet serve as evidence in drug approvals because common validation standards are missing. Regulators will need shared benchmarks before they accept simulation results in approval decisions. Transparency, reproducibility and quantified confidence will be essential, especially for drugs targeting diseases with no previously approved treatment to compare against. The outlook states plainly that these standards do not yet exist. Drug companies and quantum hardware providers are producing early data, but proprietary interests limit openness and academic papers alone do not create shared benchmarks. Hardware limits, error mitigation and encoding biological data also remain constraints, so hybrid platforms stay necessary until fault-tolerant machines arrive.